Last reviewed · How we verify
Measles Vaccine at 9 months of age
Measles Vaccine at 9 months of age is a Biologic drug developed by Medical Research Council Unit, The Gambia. It is currently in Phase 1 development. Also known as: MV.
At a glance
| Generic name | Measles Vaccine at 9 months of age |
|---|---|
| Also known as | MV |
| Sponsor | Medical Research Council Unit, The Gambia |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Pyrexia
- Gastroenteritis
- Irritability
- Pain
- Redness
- Drowsiness
- Loss of appetite
- Malaria
- Rhinitis
- Respiratory tract infection
- Otitis media
Key clinical trials
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso. (PHASE4)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency (NA)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines (PHASE1)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Measles Vaccine at 9 months of age CI brief — competitive landscape report
- Measles Vaccine at 9 months of age updates RSS · CI watch RSS
- Medical Research Council Unit, The Gambia portfolio CI
Frequently asked questions about Measles Vaccine at 9 months of age
What is Measles Vaccine at 9 months of age?
Measles Vaccine at 9 months of age is a Biologic drug developed by Medical Research Council Unit, The Gambia.
Who makes Measles Vaccine at 9 months of age?
Measles Vaccine at 9 months of age is developed by Medical Research Council Unit, The Gambia (see full Medical Research Council Unit, The Gambia pipeline at /company/medical-research-council-unit-the-gambia).
Is Measles Vaccine at 9 months of age also known as anything else?
Measles Vaccine at 9 months of age is also known as MV.
What development phase is Measles Vaccine at 9 months of age in?
Measles Vaccine at 9 months of age is in Phase 1.
What are the side effects of Measles Vaccine at 9 months of age?
Common side effects of Measles Vaccine at 9 months of age include Upper respiratory tract infection, Pyrexia, Gastroenteritis, Irritability, Pain, Redness.
Related
- Manufacturer: Medical Research Council Unit, The Gambia — full pipeline
- Also known as: MV
- Compare: Measles Vaccine at 9 months of age vs similar drugs
- Pricing: Measles Vaccine at 9 months of age cost, discount & access